The city of Huntington Beach, California, currently has 5 active clinical trials seeking participants for Arthritis research studies.
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Christine Thai, MD, Huntington Beach, California
Conditions: Rheumatoid Arthritis
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Newport Huntington Medical Group, Huntington Beach, California
Conditions: Arthritis, Psoriatic
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Newport Huntington Medical Group, Huntington Beach, California
Conditions: Arthritis, Psoriatic
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Newport Huntington Medical Group /ID# 252687, Huntington Beach, California
Conditions: Rheumatoid Arthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Newport Huntington Med Grp, Huntington Beach, California
Conditions: Rheumatoid Arthritis